Immune Checkpoint Inhibitors

Fig. 1 Schematic diagram of immune checkpoint inhibitors functioning

What are immune checkpoint inhibitors? Immune checkpoint inhibitors  are drugs that can inhibit the co-inhibitory immune checkpoint pathways , so that enhancing cancer immunity. Most of the immune checkpoint inhibitors are blocking antibodies. Sometimes fusion proteins can also act as immune checkpoint inhibitors. The immune checkpoint inhibitors have emerged as a mainstay in melanoma therapy, with potential roles in the treatment of renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC), urothelial cancer, head and neck cancer, ovarian cancer, and various lymphomas et al. With many immune checkpoint molecules becoming targets of cancer therapy, numerous immune checkpoint inhibitors is underway.

Immune Checkpoint Inhibitors under Research

  • Nivolumab, PembrolizumabIn, Pidilizumab, AMP-224
  • BMS-936559, MEDI4736, MPDL3280A, Avelumab
  • Tremelimumab, Tremelimumab
  • MGA271
  • Indoximod, INCB024360
  • Lirilumab
  • BMS-986016

Immune Checkpoint Inhibitors Related Articles

Howard (Jack) West, MD et al. Immune Checkpoint Inhibitors. JAMA Oncol. 2015;1(1):115.
Julie R. Brahmer et al. Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunol Res August 2013 1; 85.

Immune Checkpoint
What is immune checkpoint?
Immune checkpoint targets
Immune checkpoint blockade: blocking antibodies
Immune checkpoint detection: antibodies
Immune checkpoint proteins
Immune checkpoint inhibitors
Immune checkpoint therapy
Immune checkpoint pathways
PD1 / PDCD1 / CD279 immune checkpoint
VISTA / B7-H5 / GI24 immune checkpoint